Transdermal Delivery Solutions Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.tdsc.us
Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Early Phase 1:1
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Early Phase 1
1 (25.0%)Dose Response Study of Transdermal Human Insulin in Patients
Phase 2
Not yet recruiting
- Conditions
- Glucose, High Blood
- Interventions
- Device: Finger-actuated, Metered Pump Sprayer
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Transdermal Delivery Solutions Corp
- Target Recruit Count
- 30
- Registration Number
- NCT05159453
- Locations
- 🇺🇸
Langford Research Institute, Palm Beach Gardens, Florida, United States
Transdermal Insulin Response In Healthy Volunteers
Early Phase 1
Completed
- Conditions
- Pharmacodynamic Response to Small Doses of Insulin
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Transdermal Delivery Solutions Corp
- Target Recruit Count
- 7
- Registration Number
- NCT04857320
- Locations
- 🇺🇸
Langford Research Institute, Palm Beach Gardens, Florida, United States
Transdermally Delivered Human Insulin Product
Completed
- Conditions
- Hypoinsulinemia
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Transdermal Delivery Solutions Corp
- Target Recruit Count
- 1
- Registration Number
- NCT03544996
- Locations
- 🇺🇸
Langford Research Institute, Palm Beach Gardens, Florida, United States
Product Transference Study of Testagen™ TDS®-Testosterone
Phase 2
- Conditions
- Hypogonadotropism
- Interventions
- Drug: Testagen® TDS Testosterone 5% HypoSpray®
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Transdermal Delivery Solutions Corp
- Target Recruit Count
- 96
- Registration Number
- NCT02733133
A Dose Ranging Study to Examine TDS-Testosterone 5%
Phase 2
Not yet recruiting
- Conditions
- Hypogonadotropism
- Interventions
- Device: Pump Sprayer
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Transdermal Delivery Solutions Corp
- Target Recruit Count
- 48
- Registration Number
- NCT01894308
- Locations
- 🇬🇧
Advanced Therapies Centre, The London Clinic, London,, United Kingdom
News
No news found